drugset
drugset / Trial / NCT02366351

The PK/PD, Efficacy, Safety and Tolerability Study of SHR3824 in Type 2 Diabetes Mellitus Patients

NCT02366351 ↗

Phase 1 Unknown 168 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to obtain information on PK/PD, efficacy and safety of SHR3824 over 12 weeks in Chinese patients with Type 2 Diabetes. This will be done by comparing the effect of SHR3824 to placebo when given in oral doses.

Timeline

Start
2015-02
Primary completion
2016-01
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Henagliflozin Small molecule 5 mg Oral
Subject Henagliflozin Small molecule 10 mg Oral
Subject Henagliflozin Small molecule 20 mg Oral

Indications

type 2 diabetes mellitus